Ask AI
ProCE Banner Activity

Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL

Tool

Get recommendations from 2 European Union (EU) experts on the management BTK inhibitor–related adverse events in MCL for your specific patient case using this interactive decision support tool.

Released: June 25, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

George Hess, MD: consultant: AbbVie, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Gilead/Kite, Inctye, Janssen, Miltenyi, Merck Sharp & Dohme, Pierre Fabre, Regeneron, Roche, Sobi; researcher (paid to institution): AbbVie, Gilead/Kite, Janssen, Lilly, Roche; other financial or material support: AbbVie, ADC, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead/Kite, Incyte, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sobi.

Carlo Visco, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Gilead, Johnson & Johnson, Incyte, Kyowa Kirin, Lilly, Novartis, Pfizer, Roche, Sobi, Takeda.